已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies

作者
Xiaoping Luo,Ling Hou,Li Liang,Guanping Dong,Shuixian Shen,Zhuhui Zhao,Chun Xiu Gong,Yu‐Chuan Li,Minlian Du,Zhe Su,Hongwei Du,Chaoying Yan
出处
期刊:European journal of endocrinology [Oxford University Press]
卷期号:177 (2): 195-205 被引量:105
标识
DOI:10.1530/eje-16-0905
摘要

Objective We assessed the efficacy and safety of a weekly pegylated human growth hormone (PEG-rhGH) (Jintrolong) vs daily rhGH for children with growth hormone deficiency (GHD). Design Phase II and III, multicenter, open-label, randomized controlled trials. Methods 108 and 343 children with treatment-naive GHD from 6 hospitals in China were enrolled in the phase II and III studies respectively. Patients in the phase II study were randomized 1:1:1 to weekly Jintrolong (0.1 mg/kg/week PEG-rhGH complex), weekly Jintrolong (0.2 mg/kg/week PEG-rhGH complex) or daily rhGH (0.25 mg/kg/week) for 25 weeks. Patients in the phase III study were randomized in a 2:1 ratio to weekly Jintrolong (0.2 mg/kg/week) or daily rhGH (0.25 mg/kg/week) for 25 weeks. The primary endpoint for both studies was height velocity (HV) increase at the end of treatment. Other growth-related parameters, safety and compliance were also monitored. Results The phase II study established the preliminary efficacy, safety and recommended dose of Jintrolong PEG-rhGH. In the phase III study, we demonstrated significantly greater HV increases in patients receiving Jintrolong treatment (from 2.26 ± 0.87 cm/year to 13.41 ± 3.72 cm/year) vs daily rhGH (from 2.25 ± 0.82 cm/year to 12.55 ± 2.99 cm/year) at the end of treatment (P < 0.05). Additionally, significantly greater improvement in the height standard deviation scores was associated with Jintrolong throughout the treatment (P < 0.05). Adverse event rates and treatment compliance were comparable between the two groups. Conclusion Jintrolong PEG-rhGH at a dose of 0.2 mg/kg/week for 25 weeks is effective and safe for GHD treatment and is non-inferior to daily rhGH.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爱you发布了新的文献求助10
2秒前
ww完成签到,获得积分10
2秒前
这样说话发布了新的文献求助10
2秒前
win发布了新的文献求助10
3秒前
xiaowang完成签到 ,获得积分10
3秒前
高高云朵完成签到 ,获得积分10
4秒前
爱听歌的代曼完成签到 ,获得积分10
6秒前
FOD完成签到 ,获得积分10
6秒前
CoCo完成签到 ,获得积分10
6秒前
6秒前
6秒前
yangl完成签到 ,获得积分10
6秒前
简云铃完成签到,获得积分10
7秒前
坚强梦菲完成签到 ,获得积分10
8秒前
知性的水蜜桃完成签到 ,获得积分10
9秒前
慕青的应助被这样说话采纳,获得10
10秒前
111发布了新的文献求助10
11秒前
典雅狐狐完成签到,获得积分20
12秒前
wenjing完成签到 ,获得积分10
13秒前
典雅狐狐发布了新的文献求助50
22秒前
22秒前
机灵的以莲完成签到,获得积分10
24秒前
英俊的铭的应助被啊啊啊采纳,获得10
25秒前
Chem完成签到,获得积分10
28秒前
boogiepop完成签到,获得积分10
29秒前
30秒前
1733135296完成签到,获得积分10
30秒前
34秒前
henan完成签到,获得积分10
38秒前
爱you发布了新的文献求助10
39秒前
43秒前
loii举报小面包的求助涉嫌违规
44秒前
46秒前
nanfeng完成签到 ,获得积分10
47秒前
47秒前
loii举报不安迎海的求助涉嫌违规
47秒前
风中的芷珍完成签到,获得积分10
48秒前
桐桐的应助被奇迹采纳,获得10
50秒前
啊啊啊发布了新的文献求助10
51秒前
llllll完成签到 ,获得积分10
51秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179592
求助须知:如何正确求助?哪些是违规求助? 9569910
关于积分的说明 21807526
捐赠科研通 7775056
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478760